Compare CIGL & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIGL | BEAT |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 63.5M |
| IPO Year | 2025 | 2021 |
| Metric | CIGL | BEAT |
|---|---|---|
| Price | $2.04 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 12.0K | ★ 30.8M |
| Earning Date | 09-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,072,733.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.32 | N/A |
| 52 Week Low | $1.40 | $0.54 |
| 52 Week High | $31.06 | $3.48 |
| Indicator | CIGL | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 74.82 |
| Support Level | N/A | $0.66 |
| Resistance Level | N/A | $2.82 |
| Average True Range (ATR) | 0.00 | 0.26 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 0.00 | 75.67 |
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.